Trial intelligence / Profile preview

Phase 2 study of surufatinib after failure of first-line chemotherapy or anlotinib in soft tissue sarcoma

ChiCTR2100053490Phase 2Recruiting

Sponsor

Zhongshan Hospital, Fudan University

Start

Dec 2021

Modality

Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Allosteric Modulators → Classical Binding Small Molecules → Small Molecules, Irreversible Covalent Inhibitors → Covalent Small Molecules → Small Molecules

Countries

1